[go: up one dir, main page]

RU2007104028A - Ингибиторы iap - Google Patents

Ингибиторы iap Download PDF

Info

Publication number
RU2007104028A
RU2007104028A RU2007104028/04A RU2007104028A RU2007104028A RU 2007104028 A RU2007104028 A RU 2007104028A RU 2007104028/04 A RU2007104028/04 A RU 2007104028/04A RU 2007104028 A RU2007104028 A RU 2007104028A RU 2007104028 A RU2007104028 A RU 2007104028A
Authority
RU
Russia
Prior art keywords
alkyl
compound according
aryl
cycloalkyl
amino
Prior art date
Application number
RU2007104028/04A
Other languages
English (en)
Other versions
RU2401840C2 (ru
Inventor
Фредерик КОЭН (US)
Фредерик Коэн
Курт ДЕЗЕЙ (US)
Курт ДЕЗЕЙ
Уэйн Дж. ФЭЙРБРОЗЕР (US)
Уэйн Дж. ФЭЙРБРОЗЕР
Байн нь ФЭН (US)
Байнянь ФЭН
Джон ФЛАЙГЭР (US)
Джон ФЛАЙГЭР
Дьюис Дж. ГАЗЗАРД (US)
Дьюис Дж. ГАЗЗАРД
Вики С о-Вэй ЦЗУИ (US)
Вики Сяо-Вэй ЦЗУИ
Original Assignee
Дженентек, Инк. (Us)
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. (Us), Дженентек, Инк. filed Critical Дженентек, Инк. (Us)
Publication of RU2007104028A publication Critical patent/RU2007104028A/ru
Application granted granted Critical
Publication of RU2401840C2 publication Critical patent/RU2401840C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (21)

1. Соединение формулы I
Figure 00000001
где каждый из X1, X2 и X3 независимо представляет собой O или S; Y представляет собой (CHR7)n, O или S; где n = 1 или 2, и R7 представляет собой H, галоген, алкил, арил, аралкил, амино, ариламино, алкиламино, аралкиламино, алкокси, арилокси или аралкилокси;
A представляет собой 5-членный гетероцикл, содержащий от 1 до 4 гетероатомов, необязательно замещенных амино, гидроксилом, меркапто, галогеном, карбоксилом, амидино, гуанидино, алкилом, алкокси, арилом, арилокси, ацилом, ацилокси, ациламино, алкоксикарбониламино, циклоалкилом, алкилтио, алкилсульфинилом, алкилсульфонилом, аминосульфонилом, алкиламиносульфонилом, алкилсульфониламино или гетероциклом; где каждое алкильное, алкокси-, арильное, арилокси-, ацильное, ацилокси-, ациламино-, циклоалкильное и гетероциклическое замещение необязательно замещено гидроксилом, галогеном, меркапто, карбоксилом, алкилом, алкокси, галогеналкилом, амино, нитро, циано, циклоалкилом, арилом или гетероциклом;
R1 представляет собой H или R1 и R2 вместе образуют 5-8 членное кольцо;
R2 представляет собой алкил, циклоалкил, циклоалкилалкил, арил, аралкил, гетероцикл или гетероциклический алкил; и каждый из них необязательно замещен гидроксилом, меркапто, галогеном, амино, карбоксилом, алкилом, галогеналкилом, алкокси или алкилтио;
R3 представляет собой H или алкил;
каждый из R4 и R4' независимо представляет собой H, гидроксил, амино, алкил, арил, аралкил, циклоалкил, циклоалкилалкил, гетероарил или гетероарилалкил, где каждый алкил, арил, аралкил, циклоалкил, циклоалкилалкил, гетероарил и гетероарилалкил необязательно замещен галогеном, гидроксилом, меркапто, карбоксилом, алкилом, алкокси, амино и нитро;
каждый из R5, и R5' независимо представляет собой H или алкил;
каждый из R6, и R6' независимо представляет собой H, алкил, арил или аралкил; а также их соли и сольваты.
2. Соединение по п.1, где кольцо A имеет формулу IIa или IIb
Figure 00000002
где Q1 представляет собой NR8, O или S; каждый из Q2, Q3, Q4, Q5, Q6, Q7, и Q8 независимо представляет собой CR9 или N; где R9 представляет собой H, амино, гидроксил, меркапто, галоген, карбоксил, амидино, гуанидино, алкил, алкокси, арил, арилокси, ацил, ацилокси, ациламино, циклоалкил или гетероцикл; где каждое алкильное, алкокси-, арильное, арилокси-, ацильное, ацилокси-, ациламино-, циклоалкильное и гетероциклическое замещение необязательно замещено гидроксилом, галогеном, меркапто, карбоксилом, алкилом, галогеналкилом, амино, нитро, циклоалкилом, арилом или гетероциклом; R8 представляет собой H, алкил, ацил, арил, циклоалкил или гетероцикл; где каждый алкил, арил, циклоалкил и гетероцикл необязательно замещен гидроксилом, галогеном, меркапто, карбоксилом, алкилом, галогеналкилом, амино, нитро, циклоалкилом, арилом или гетероциклом; и Q9 представляет собой CH или N.
3. Соединение по п.1, где кольцо A выбрано из группы, состоящей из следующего
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
где R8 представляет собой H, алкил или ацил.
4. Соединение по п.3, где R8 представляет собой H.
5. Соединение по п.1, где R1 и R2 вместе образуют 5-8 членное кольцо.
6. Соединение по п.1, где R1 представляет собой H.
7. Соединение по п.1, где R2 представляет собой алкил или циклоалкил.
8. Соединение по п.1, где R2 представляет собой изопропил, трет-бутил или циклогексил.
9. Соединение по п.1, где R3 представляет собой метил.
10. Соединение по п.1, где R4 представляет собой H или метил, и R4' представляет собой H.
11. Соединение по п.1, где каждый из R5 и R5' независимо представляет собой H или метил.
12. Соединение по п.1, где каждый из R6 и R6' независимо представляет собой H или метил.
13. Соединение по п.1, где каждый из X1, X2 и X3 представляет собой O.
14. Соединение по п.2, где R1 представляет собой H; R2 представляет собой изопропил, трет-бутил или циклогексил; R3 представляет собой метил; R4 представляет собой H или метил, и R4' представляет собой H, R5 и R5' представляют собой H или метил; X1, X2 и X3 представляют собой O.
15. Способ индуцирования апоптоза в клетке, включающий в себя введение в указанную клетку соединения по п.1.
16. Способ сенсибилизации клетки к апоптотическому сигналу, включающий в себя введение в указанную клетку соединения по п.1.
17. Способ по п.16, согласно которому указанный апоптотический сигнал индуцируют посредством приведения указанной клетки в контакт с соединением, выбранным из группы, состоящей из цитарабина, флударабина, 5-фтор-2'-дезоксиуридина, гемцитабина, метотрексата, блеомицина, цисплатина, циклофосфамида, адриамицина (доксорубицина), митоксантрона, камптотецина, топотекана, колцемида, колхицина, паклитаксела, винбластина, винкристина, тамоксифена, финастерида, таксотера и митомицина C.
18. Способ по п.16, согласно которому указанный апоптотический сигнал индуцируют посредством приведения указанной клетки в контакт с Apo2L/TRAIL.
19. Способ ингибирования связывания белка IAP с белком каспазы, включающий в себя контактирование указанного белка IAP с соединением по п.1.
20. Способ лечения заболевания или состояния, ассоциированного с повышенной экспрессией IAP у млекопитающего, включающий в себя введение указанному млекопитающему эффективного количества соединения по п.1.
21. Способ лечения онкологических заболеваний, включающий в себя введение указанному млекопитающему эффективного количества соединения по п.1.
RU2007104028/04A 2004-07-02 2005-07-05 Ингибиторы iap RU2401840C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58550104P 2004-07-02 2004-07-02
US60/585,501 2004-07-02

Publications (2)

Publication Number Publication Date
RU2007104028A true RU2007104028A (ru) 2008-08-10
RU2401840C2 RU2401840C2 (ru) 2010-10-20

Family

ID=35311854

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007104028/04A RU2401840C2 (ru) 2004-07-02 2005-07-05 Ингибиторы iap

Country Status (21)

Country Link
US (4) US7244851B2 (ru)
EP (1) EP1778718B1 (ru)
JP (3) JP4850175B2 (ru)
KR (2) KR100926203B1 (ru)
CN (1) CN101035802A (ru)
AU (2) AU2005270104A1 (ru)
BR (1) BRPI0511350A (ru)
CA (1) CA2570321C (ru)
DK (1) DK1778718T3 (ru)
ES (1) ES2524449T3 (ru)
IL (1) IL179854A (ru)
MX (1) MXPA06014969A (ru)
NO (1) NO341816B1 (ru)
NZ (1) NZ588799A (ru)
PL (1) PL1778718T3 (ru)
PT (1) PT1778718E (ru)
RS (1) RS53734B1 (ru)
RU (1) RU2401840C2 (ru)
SI (1) SI1778718T1 (ru)
WO (1) WO2006014361A1 (ru)
ZA (1) ZA200700032B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2418807C2 (ru) * 2005-10-25 2011-05-20 Аегера Терапьютикс Инк. Соединения, связывающие bir домены iap

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7646707B2 (en) * 2003-12-23 2010-01-12 At&T Intellectual Property I, L.P. Method and system for automatically renaming logical circuit identifiers for rerouted logical circuits in a data network
CA2553871A1 (en) * 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Smac peptidomimetics and the uses thereof
CN1960728A (zh) * 2004-01-16 2007-05-09 密歇根大学董事会 构象受限的smac模拟物及其应用
PL2253614T3 (pl) 2004-04-07 2013-03-29 Novartis Ag Inhibitory IAP
SI1778718T1 (sl) * 2004-07-02 2015-01-30 Genentech, Inc. Inhibitorji IAP
US7674787B2 (en) * 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
EP1773348A4 (en) * 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc TETRA PEPTIDE ANALOGS
ES2475207T3 (es) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
KR20120127754A (ko) 2004-12-20 2012-11-23 제넨테크, 인크. Ｉａｐ의 피롤리딘 억제제
DK1851200T3 (da) * 2005-02-25 2014-04-14 Tetralogic Pharm Corp Dimere iap-inhibitorer
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
US20070042428A1 (en) * 2005-08-09 2007-02-22 Stacy Springs Treatment of proliferative disorders
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
WO2007106192A2 (en) * 2005-12-19 2007-09-20 Genentech, Inc. Inhibitors of iap
TWI504597B (zh) * 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
SG10201407457UA (en) 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
WO2008014240A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
AR064235A1 (es) 2006-07-24 2009-03-25 Tetralogic Pharmaceuticals Cor Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer
US20100144650A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5228202B2 (ja) * 2006-07-24 2013-07-03 テトラロジック ファーマシューティカルズ コーポレーション 二量体ｉａｐアンタゴニスト
US20100143499A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110217A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
RU2009110254A (ru) * 2006-08-24 2010-09-27 Новартис АГ (CH) Производные 2-(пиразин-2-ил)тиазола и 2-(1н-пиразол-3-ил)тиразола и связанные с ним соединения в качестве ингибиторов стеароил-соа десатуразы для лечения метаболических, сердечно-сосудистых и других нарушений
BRPI0718509A2 (pt) * 2006-09-22 2015-09-29 Novartis Ag compostos orgânicos heterocíclicos
CA2666112A1 (en) 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors
WO2008079735A1 (en) * 2006-12-19 2008-07-03 Genentech, Inc. Imidazopyridine inhibitors of iap
CA2672776A1 (en) * 2006-12-20 2008-06-26 Novartis Ag 2-substituted 5-membered heterocycles as scd inhibitors
CA2684169C (en) * 2007-04-12 2012-06-19 Joyant Pharmaceuticals, Inc. Smac mimetic dimers and trimers useful as anti-cancer agents
CA2683392A1 (en) * 2007-04-30 2008-11-06 Genentech, Inc. Inhibitors of iap
US20110008802A1 (en) * 2007-05-07 2011-01-13 Tetralogic Pharmaceuticals Corp. TNFalpha GENE EXPRESSION AS A BIOMARKER OF SENSITIVITY TO ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS
WO2008144925A1 (en) * 2007-05-30 2008-12-04 Aegera Therapeutics Inc. Iap bir domain binding compounds
BRPI0905664A2 (pt) * 2008-01-11 2015-07-07 Genentech Inc "composto, método de indução de apoptose, método de sensibilização de uma célula, método para inibir a ligação de uma proteína, método para tratar uma doença e método para tratar câncer"
WO2009136290A1 (en) * 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US20110171171A1 (en) * 2008-06-27 2011-07-14 Aegera Therapeutics, Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
JP2011529962A (ja) * 2008-08-02 2011-12-15 ジェネンテック， インコーポレイテッド Ｉａｐのインヒビター
CA2730357A1 (en) * 2008-08-16 2010-02-25 Genetech, Inc. Azaindole inhibitors of iap
CA2736505A1 (en) 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. Iap inhibitors
FR2939073B1 (fr) 2008-12-03 2010-12-31 Sidel Participations Formage des recipients avec contre-pression localisee
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
US20120196793A1 (en) 2009-09-18 2012-08-02 Firestone Brant G Biomarkers for iap inhibitor compounds
EP2493879B1 (en) 2009-10-28 2014-05-14 Joyant Pharmaceuticals, Inc. Dimeric smac mimetics
CN102050867A (zh) * 2009-11-10 2011-05-11 上海艾力斯医药科技有限公司 四肽类似物、制备方法及其应用
KR20120140658A (ko) 2010-02-12 2012-12-31 파마사이언스 인크. Ｉａｐ ｂｉｒ 도메인 결합 화합물
BR112012026530B1 (pt) 2010-04-16 2018-03-20 Bayer Intellectual Property Gmbh Compostos heterocíclicos como pesticidas, composição os compreendendo e suas utilizações, bem como método para controle de pragas de pragas
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
WO2013043591A1 (en) * 2011-09-21 2013-03-28 Albert Einstein College Of Medicine Of Yeshiva University Combination therapy for cancer
WO2013049350A1 (en) 2011-09-30 2013-04-04 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
NO2755614T3 (ru) * 2012-01-03 2018-03-31
CA2871995A1 (en) 2012-05-04 2013-11-07 Novartis Ag Biomarkers for iap inhibitor therapy
CA2896577C (en) 2012-11-30 2024-01-23 Sanford-Burnham Medical Research Institute Inhibitor of apoptosis protein (iap) antagonists
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
JP6333943B2 (ja) 2013-03-15 2018-05-30 ノバルティス アーゲー 抗体薬物コンジュゲート
CN105451726B (zh) 2013-06-25 2021-03-16 沃尔特和伊利莎豪医学研究所 治疗细胞内感染的方法
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
PL3083616T3 (pl) 2013-12-20 2021-12-06 Astex Therapeutics Limited Bicykliczne związki heterocykliczne i ich zastosowania w terapii
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2015168835A1 (en) * 2014-05-05 2015-11-12 Empire Technology Development Llc Composite task processor
EP3151920B1 (en) 2014-06-04 2025-08-06 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
BR112017001588A2 (pt) 2014-08-12 2017-11-21 Novartis Ag conjugados de anticorpo/fármaco anti-cdh6
GB201414730D0 (en) 2014-08-19 2014-10-01 Tpp Global Dev Ltd Pharmaceutical compound
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
HK1245791A1 (zh) 2015-01-20 2018-08-31 阿尔维纳斯运营股份有限公司 用於雄激素受体的靶向降解的化合物和方法
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
DK3472149T3 (da) 2016-06-21 2023-11-27 Orion Ophthalmology LLC Heterocykliske prolinamidderivater
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
WO2018102067A2 (en) 2016-11-01 2018-06-07 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
JP6957620B2 (ja) 2016-12-01 2021-11-02 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体およびテトラヒドロイソキノリン誘導体
JP2020505327A (ja) 2016-12-23 2020-02-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES
KR20250117470A (ko) 2016-12-23 2025-08-04 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
JP7266526B6 (ja) 2017-01-26 2024-02-15 アルビナス・オペレーションズ・インコーポレイテッド エストロゲン受容体タンパク質分解性の調節因子およびその関連方法
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
US11179413B2 (en) 2017-03-06 2021-11-23 Novartis Ag Methods of treatment of cancer with reduced UBB expression
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
CN111107868A (zh) 2017-05-24 2020-05-05 诺华股份有限公司 抗体细胞因子移植蛋白及使用方法
SG11202004377XA (en) 2017-11-13 2020-06-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Smac mimetics used as iap inhibitors and use thereof
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
JP7161849B2 (ja) * 2018-01-24 2022-10-27 株式会社クラレ 第一級アミンの製造方法
CN111655713B (zh) * 2018-02-09 2023-06-27 广东东阳光药业有限公司 Iap抑制剂及其在药物中的应用
JP7720698B2 (ja) 2018-04-04 2025-08-08 アルビナス・オペレーションズ・インコーポレイテッド タンパク質分解の調節因子および関連する使用方法
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020012334A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
WO2020023851A1 (en) 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
WO2020041331A1 (en) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
JP2022500368A (ja) 2018-09-07 2022-01-04 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. 急速進行性線維肉腫ポリペプチドの標的分解のための多環式化合物および方法
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
EP3897637A1 (en) 2018-12-20 2021-10-27 Novartis AG Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP4406555A3 (en) 2018-12-21 2024-11-06 Novartis AG Antibodies to pmel17 and conjugates thereof
ES2982474T3 (es) 2019-02-15 2024-10-16 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
AU2020233068B2 (en) * 2019-03-07 2025-04-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combination of IAP inhibitor and immune checkpoint inhibitor
ES2976001T3 (es) * 2019-05-10 2024-07-19 Chia Tai Tianqing Pharmaceutical Group Co Ltd Cristalización de un mimético de SMAC utilizado como inhibidor de IAP y método de preparación del mismo
WO2021011913A1 (en) 2019-07-17 2021-01-21 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
US20220257698A1 (en) 2019-08-02 2022-08-18 Lanthiopep B.V. Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
MX2022002415A (es) 2019-08-26 2022-03-22 Arvinas Operations Inc Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
IL293889A (en) 2019-12-20 2022-08-01 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
JP2023510426A (ja) 2020-01-20 2023-03-13 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
CN111205232B (zh) * 2020-02-26 2022-07-01 浙江天宇药业股份有限公司 一种替格瑞洛中间体的合成方法
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
AU2021288224A1 (en) 2020-06-11 2023-01-05 Novartis Ag ZBTB32 inhibitors and uses thereof
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
US12162859B2 (en) 2020-09-14 2024-12-10 Arvinas Operations, Inc. Crystalline and amorphous forms of a compound for the targeted degradation of estrogen receptor
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022221720A1 (en) 2021-04-16 2022-10-20 Novartis Ag Antibody drug conjugates and methods for making thereof
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
CN119301125A (zh) 2022-07-26 2025-01-10 诺华股份有限公司 Akr1c3依赖性kars抑制剂的晶型
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
AU2024212035A1 (en) 2023-01-26 2025-08-14 Arvinas Operations, Inc. Cereblon-based kras degrading protacs ans uses related thereto

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE430062B (sv) * 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
DE2714880A1 (de) * 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0217634B1 (en) * 1985-09-26 1992-06-10 Beckman Research Institute of the City of Hope Sequencing of peptides
US4935494A (en) * 1988-11-15 1990-06-19 City Of Hope C-terminal peptide and protein sequencing
DK167813B1 (da) * 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
WO1992001938A1 (en) 1990-07-20 1992-02-06 City Of Hope Derivatization of c-terminal proline
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5559209A (en) * 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
IL138469A0 (en) * 1998-03-19 2001-10-31 Vertex Pharma Caspase inhibitors and pharmaceutical compositions containing the same
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6472172B1 (en) * 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
JP2002533726A (ja) 1998-12-28 2002-10-08 サネシス ファーマシューティカルス インコーポレイテッド 結合のための小有機分子リガンドの同定
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
WO2002016418A2 (en) 2000-08-24 2002-02-28 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
US6992063B2 (en) * 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
AU2001293189A1 (en) 2000-09-29 2002-04-08 Trustees Of Princeton University Compositions and methods for regulating apoptosis
WO2002030959A2 (en) 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
WO2003010184A2 (en) 2001-02-08 2003-02-06 Thomas Jefferson University A conserved xiap-interaction motif in caspase-9 and smac/diablo for mediating apoptosis
JP2004531731A (ja) 2001-05-31 2004-10-14 ザ トラスティーズ オブ プリンストン ユニバーシテイ Ｉａｐ結合ペプチドおよびｉａｐに結合する化合物を同定するアッセイ
WO2003040172A2 (en) * 2001-11-09 2003-05-15 Aegera Therapeutics, Inc. Methods and reagents for peptide-bir interaction screens
WO2003086470A2 (en) 2002-04-17 2003-10-23 Deutsches Krebsforschungszentrum Smac-peptides as therapeutics against cancer and autoimmune diseases
WO2004005248A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
EP1578777B1 (en) 2002-07-15 2008-11-26 The Trustees of Princeton University Iap binding compounds
AU2003290083A1 (en) 2002-08-13 2004-03-11 Cell Center Cologne Gmbh Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin's lymphomas
CA2514316A1 (en) 2003-02-07 2004-08-26 Genentech, Inc. Compositions and methods for enhancing apoptosis
US20040171554A1 (en) 2003-02-07 2004-09-02 Genentech, Inc. Compositions and methods for enhancing apoptosis
IL156263A0 (en) 2003-06-02 2004-01-04 Hadasit Med Res Service Livin-derived peptides, compositions and uses thereof
CA2543897A1 (en) 2003-11-13 2005-06-02 Genentech, Inc. Compositions and methods for screening pro-apoptotic compounds
PL2253614T3 (pl) 2004-04-07 2013-03-29 Novartis Ag Inhibitory IAP
SI1778718T1 (sl) * 2004-07-02 2015-01-30 Genentech, Inc. Inhibitorji IAP
ES2475207T3 (es) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2418807C2 (ru) * 2005-10-25 2011-05-20 Аегера Терапьютикс Инк. Соединения, связывающие bir домены iap

Also Published As

Publication number Publication date
IL179854A (en) 2014-04-30
PT1778718E (pt) 2014-12-03
ES2524449T3 (es) 2014-12-09
US20060014700A1 (en) 2006-01-19
IL179854A0 (en) 2007-05-15
US20100256115A1 (en) 2010-10-07
JP2011251990A (ja) 2011-12-15
JP2014058522A (ja) 2014-04-03
US20070299052A1 (en) 2007-12-27
KR100984459B1 (ko) 2010-09-29
AU2009243421A1 (en) 2009-12-17
CN101035802A (zh) 2007-09-12
MXPA06014969A (es) 2007-02-08
US8980837B2 (en) 2015-03-17
PL1778718T3 (pl) 2015-03-31
KR100926203B1 (ko) 2009-11-09
BRPI0511350A (pt) 2007-12-04
KR20090089481A (ko) 2009-08-21
WO2006014361A1 (en) 2006-02-09
NZ588799A (en) 2012-06-29
RU2401840C2 (ru) 2010-10-20
EP1778718B1 (en) 2014-10-08
NO20070606L (no) 2007-03-30
SI1778718T1 (sl) 2015-01-30
AU2009243421B2 (en) 2011-07-14
AU2005270104A1 (en) 2006-02-09
ZA200700032B (en) 2008-05-28
US20120202750A1 (en) 2012-08-09
KR20070035060A (ko) 2007-03-29
CA2570321A1 (en) 2006-02-09
US7244851B2 (en) 2007-07-17
JP5558428B2 (ja) 2014-07-23
RS53734B1 (sr) 2015-06-30
JP2008505904A (ja) 2008-02-28
DK1778718T3 (da) 2014-11-10
US8110568B2 (en) 2012-02-07
JP4850175B2 (ja) 2012-01-11
EP1778718A1 (en) 2007-05-02
NO341816B1 (no) 2018-01-29
CA2570321C (en) 2013-10-08

Similar Documents

Publication Publication Date Title
RU2007104028A (ru) Ингибиторы iap
RU2009144094A (ru) Ингибиторы iap
JP2011251990A5 (ru)
RU2009127800A (ru) Имидазопиридиновые ингибиторы iap
JP2010526079A5 (ru)
RU2008129683A (ru) Ингибиторы iap
RU2010133548A (ru) Ингибиторы iap
RU2327701C2 (ru) Нуклеозидные производные и фармацевтическая композиция, обладающая антивирусной активностью в отношении hcv
RU2350605C2 (ru) Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
PE20050953A1 (es) Compuestos macrociclicos como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
DE69835430D1 (de) Sulfonamidderivate, ihre herstellung und verwendung
RU2017145026A (ru) Соединение, ингибирующее brk
RU2007123235A (ru) Противоопухолевые соединения
JP2010509359A5 (ru)
EA200800924A1 (ru) Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортера
RU2006143683A (ru) Циклические пиримидиноновые соединения и их применение
CY1112200T1 (el) Συνδυασμοι για τη θεραπεια ασθενειων που ενεχουν κυτταρικο πολλαπλασιασμο
RU2005140570A (ru) Фармацевтическая композиция, содержащая ингибитор гистондеацетилазы
EA200700189A1 (ru) Производные хиназолина в качестве ингибиторов parp
JP2009520041A5 (ru)
JP2018058822A5 (ru)
RU2014130171A (ru) Ингибиторы iap
RU2006109004A (ru) 7-аминоалкилиденилгетероциклические хинолоны и нафтиридоны
EA200600694A1 (ru) Дисульфидные, сульфидные, сульфоксидные и сульфоновые производные циклических сахаров и их применение